Imatinib inhibits in vitro proliferation of cells derived from a pleural solitary fibrous tumor expressing platelet-derived growth factor receptor-beta

• Published in: Lung cancer (Amsterdam, Netherlands) Vol. 64; no. 2; pp. 244 - 246
• Main Authors: Prunotto, Marco, Bosco, Martino, Daniele, Lorenzo, Macri’, Luigia, Bonello, Lisa, Schirosi, Laura, Rossi, Giulio, Filosso, Pierluigi, Mussa, Baudolino, Sapino, Anna
• Format: Journal Article
• Language: English
• Published: Oxford Elsevier Ireland Ltd 01.05.2009; Elsevier
• Subjects: Aged; Antineoplastic Agents - pharmacology; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Benzamides; Biological and medical sciences; Blotting, Western; Cell Proliferation - drug effects; Cells, Cultured; Cisplatin - administration & dosage; Female; Fluorescent Antibody Technique; Fluorouracil - administration & dosage; Gleevec; Hematology, Oncology and Palliative Medicine; Humans; Imatinib; Imatinib Mesylate; In Vitro Techniques; Medical sciences; Mutational analysis; Neoplasm Recurrence, Local - metabolism; Neoplasm Recurrence, Local - pathology; PDGFR; Piperazines - pharmacology; Pleura; Pneumology; Pneumonectomy; Pulmonary/Respiratory; Pyrimidines - pharmacology; Radiotherapy; Receptor, Platelet-Derived Growth Factor alpha - biosynthesis; Receptor, Platelet-Derived Growth Factor beta - biosynthesis; Receptor, Platelet-Derived Growth Factor beta - drug effects; Solitary fibrous tumor; Solitary Fibrous Tumor, Pleural - metabolism; Solitary Fibrous Tumor, Pleural - pathology; Solitary Fibrous Tumor, Pleural - therapy; Tumors; Tumors of the respiratory system and mediastinum; PDGFR; Imatinib; Mutational analysis; Gleevec; Solitary fibrous tumor; Pleura; Respiratory disease; Proliferation; Malignant tumor; In vitro; Chenopodiaceae; Beta; Pleural tumor; Cancerology; Dicotyledones; Angiospermae; Pleural disease; Spermatophyta; Mutation; Cell; Platelet derived growth factor; Cancer; Pneumology; Biological receptor
• ISSN: 0169-5002; 1872-8332
• DOI: 10.1016/j.lungcan.2008.10.013

Abstract We examined the in vitro effects of imatinib (Novartis Pharma AG, Basel, Switzerland) as a possible inhibitor of PDGFR pathway on cells derived from a recurrence of a pleural malignant solitary fibrous tumor (SFT). Primary cell culture was characterised by immunofluorescence. SFT-derived cells were treated with imatinib at different time points. Western blotting for PDGFR-β, phospho-PDGFR-β or smooth muscle actin (SMA) was performed before and after 96 h of treatment with imatinib. SFT-derived cells treated with imatinib for 96 h showed a dose dependent decrease of Ki67 expression. Results were confirmed by growth curve. Western blotting showed that PDGFR-β was highly expressed and phosphorylated in SFT-derived cells and imatinib treatment reduced PDGFR-β phosphorylation and SMA expression. With the limit of experimental findings, our results support a possible future application of imatinib as a candidate molecule in the target therapy of malignant SFTs over-expressing wild-type PDGFR.